Levetiracetam Ratiopharm (Levetiracetam)

Levetiracetam binds to the synaptic vesicle protein SV2A, modulating calcium‑dependent neurotransmitter release. This reduces neuronal excitability and limits the spread of abnormal electrical activity that causes seizures.

The prescribed dose of Levetiracetam Ratiopharm is determined by the treating physician based on the patient’s clinical condition, seizure type, renal function and other individual factors.

Levetiracetam is classified as pregnancy category B, indicating that animal studies have not shown risk but adequate human data are lacking. It should be used only if the potential benefit justifies the potential risk, and breastfeeding decisions should be made with a healthcare professional.

Enquiries are submitted on the product page at gnhindia.com, where you specify the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and import documentation.

Levetiracetam offers a distinct mechanism by targeting SV2A, which differs from sodium‑channel blockers or GABA‑enhancers. It generally has fewer drug‑enzyme interactions, a rapid onset when given intravenously, and a favorable tolerability profile compared with many older antiepileptics.

Store the intravenous solution at ambient temperature, preferably below 25 °C. Keep the vial in its original packaging, protect it from moisture and direct light, and avoid freezing.

Levetiracetam Ratiopharm is administered intravenously by a healthcare professional. The solution is diluted according to the prescribing information and infused over the recommended period, usually as a slow injection or short infusion.

Serious risks include severe allergic reactions such as anaphylaxis, psychiatric disturbances like depression or suicidal thoughts, and rare skin conditions such as Stevens‑Johnson syndrome. Prompt medical attention is required if any of these occur.

Patients with known hypersensitivity to levetiracetam or any component of the formulation should avoid its use. Caution is also advised for individuals with severe renal impairment, uncontrolled psychiatric illness, or those taking interacting medications listed as major interactions.